Skip to content
← Full study record

NCT01286077 · OUTCOME

Change From Baseline in Biochemical Bone Markers: Dickkopf Homolog 1 (DKK-1)

Velcade Consolidation Bone Study · Source last updated 2016-05-30

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
Picomole per liter
Interval / dispersion
Standard Deviation
Time frame
Baseline up to end of study (approximately 4 years 7 months)

What was measured

Bone markers Dickkopf homolog 1 (DKK-1) was measured on serum samples.

Analysis population: FAS was used for analysis. "N" (number of subjects analyzed) signifies the subjects evaluable this measure and n=number pf participants analysed for this outcome measure at specific time point. Missing data was imputed by last observation carried forward (LOCF) method.

Groups in this outcome

Bortezomib

bortezomib (Velcade) 1.6 mg/m² bolus injection on Days 1, 8, 15 and 22 every 5 weeks for 4 cycles

Non-treated Control

no treatment, observation only

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Bortezomib43
Non-treated Control40

Reported measurements

Source class 1
Values in Picomole per liter · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Bortezomib-39.3182.87Not reportedNot reportedNot reported
Non-treated Control-25.1587.20Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        82.87
        value
        -39.31
      2. group Id
        OG001
        spread
        87.20
        value
        -25.15
denoms
  1. counts
    1. group Id
      OG000
      value
      43
    2. group Id
      OG001
      value
      40
    units
    Participants
description
Bone markers Dickkopf homolog 1 (DKK-1) was measured on serum samples.
dispersion Type
Standard Deviation
groups
  1. description
    bortezomib (Velcade) 1.6 mg/m² bolus injection on Days 1, 8, 15 and 22 every 5 weeks for 4 cycles
    id
    OG000
    title
    Bortezomib
  2. description
    no treatment, observation only
    id
    OG001
    title
    Non-treated Control
param Type
MEAN
population Description
FAS was used for analysis. "N" (number of subjects analyzed) signifies the subjects evaluable this measure and n=number pf participants analysed for this outcome measure at specific time point. Missing data was imputed by last observation carried forward (LOCF) method.
reporting Status
POSTED
time Frame
Baseline up to end of study (approximately 4 years 7 months)
title
Change From Baseline in Biochemical Bone Markers: Dickkopf Homolog 1 (DKK-1)
type
SECONDARY
unit Of Measure
Picomole per liter

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice